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Frequently amplified regions of the cancer genome contain well-known oncogenes. In this issue of Cancer
Cell, Hu and colleagues discover that FAL1, a long noncoding RNA is encoded in one of these regions.
FAL1 acts as an oncogene by stabilizing BMI1, which results in the repression of CDKN1A expression.Genomic instability in cancer leads to
rearrangements, amplifications, and de-
letions of entire DNA fragments. Somatic
copy-number alterations (SCNAs) pro-
vide a mechanism for modifying the
gene dose to confer selective advantage
for tumor cells. The amplification of a
gene can lead to its overexpression:
well-known oncogenes such as EGFR,
ERBB2, and MYC are contained in
frequently-amplified regions (Beroukhim
et al., 2010).
Amplicon length can vary from several
kilobases to megabases, often contain-
ing many genes. A big challenge for
cancer biology is to identify which of
the genes contained in an amplified
region play a causal role in carcino-
genesis. The challenge is even greater
if we take a closer look and consider
not only the protein-coding genes but
also the long noncoding RNAs (lncRNAs)
present in these amplified regions.
Although growing evidence relates some
lncRNAs with cancer progression, the
function of the vast majority of lncRNAs
remains to be determined, complicating
the task.
In this issue of Cancer Cell, Hu et al.
(2014) rise to this challenge by focusing
their study on the noncoding portion of
the genome to identify lncRNAs that areclinically relevant to cancer. They show
that a large number of lncRNAs are inside
somatic copy number alterations. Some
of these altered regions do not contain
any previously identified cancer-associ-
ated protein-coding genes, suggesting
that the noncoding genes could be
responsible for driving the disease. These
analyses reveal a set of noncoding candi-
date cancer drivers and highlight the po-
tential role of lncRNAs in the development
of cancer.
By integrating SNP arrays of 2,394
tumors of 12 cancer types with gene
expression microarrays of 40 cancer cell
lines, Hu et al. (2014) identify a set of ex-
pressed lncRNAs frequently amplified in
tumors in the study. From this set, the au-
thors explore in depth the role of a novel
lncRNA and putative oncogene named
focally amplified lncRNA on chromosome
1 or FAL1.
More detailed analysis of FAL1 copy
number gain showed that this alteration
was frequently present in epithelial
tumors. Interestingly, the high level of
FAL1 expression is not always associated
with its focal amplification, suggesting
that other mechanisms may contribute
to its increased expression in cancer
cells. Further analysis using an ovarian
cancer tumor cohort revealed a higherexpression of FAL1 in late-stage tumors
and an association between the genomic
amplification of FAL1 and decreased pa-
tient survival.
Besides the strong genetic evidence
provided by the SCNA analysis, FAL1
displayed oncogenic features in several
functional experiments. Overexpression
of FAL1 resulted in an increase in the
colony-formation capacity of cells, an
effect enhanced by the additional over-
expression of MYC or mutant RAS.
These experiments not only indicate
that FAL1 can act in cooperation with
other oncogenes, but also suggest that
the lncRNA exerts its functions in trans.
In fact, downregulation of FAL1 by short
hairpin RNAs showed no effect on the
expression levels of other genes present
in the amplicon. Interestingly, among
these genes is MCL1, a known protein-
coding oncogene (Beroukhim et al.,
2010). However, alteration of FAL1 levels
had no effect on MCL1, suggesting an
independent role. Similar to FAL1, the
oncogenic lncRNA PCAT-1 has been
recently shown to appear coamplified
with an oncogene (MYC in this case),
while it functions independently of its
neighboring oncogene, i.e., via a MYC-
independent mechanism (Prensner et al.,
2011). In contrast, a recent study (Tsengeptember 8, 2014 ª2014 Elsevier Inc. 303
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Figure 1. A Working Model for FAL1 as an Oncogene
FAL1 (red ribbon) maps to a focally amplified region of chr1q21 and exerts its
function by interacting with BMI1/PRC1, promoting its stabilization by block-
ing its proteasomal degradation. This has an effect on the ubiquitylation levels
of H2AK119 target genes such as CDKN1A, potentially explaining FAL1’s
oncogenic role in cancer.
Cancer Cell
Previewset al., 2014) demonstrated
that the amplification of
the lncRNA PVT1 correlates
with MYC copy number
gain. More strikingly, gain of
PVT1 increases MYC protein
levels, demonstrating a de-
pendency of coamplified
genes by a cis-regulatory
mechanism. In the case of
FAL1, overexpression and
inhibition experiments indi-
cate that FAL1 is a trans-
acting lncRNA. Still, it re-
mains to be determined if
the simultaneous amplifica-
tion of MCL1 and FAL1
have downstream effects
that can provide increased
advantage to the cancer
cells. Further genetic studies
can help elucidate these
questions.
The authors also addressthe intriguing question of how FAL1 can
exert its oncogenic activities. They show
that FAL1 physically interacts with the
protein BMI1, a ring-finger member of
the polycomb repressive complex 1
(PRC1). While several lncRNAs have
been shown to interact with PRC2 and
other chromatin modifiers to regulate their
targeting to specific gene loci (Marchese
and Huarte, 2014), FAL1 association to
BMI1 results in BMI1 protein stabilization
instead, with a subsequent increase in
the global levels of active PRC1 complex
and H2AK119 ubiquitylation (Figure 1).
Intriguingly, recent work by Howard
Chang’s group showed that the stability
of WDR5, a subunit of MLL chromatin
complex, is regulated by binding to
lncRNAs (Yang et al., 2014). Because of
its mechanism of action, FAL1 may
belong to a class of nuclear lncRNAs
whose ability to bind a chromatin complex
appears to be essential for protein stabil-
ity. Hu et al. (2014) further explore FAL1304 Cancer Cell 26, September 8, 2014 ª201binding to BMI1, defining a 116-nt frag-
ment in FAL1 responsible for this in-
teraction. This region may contain a
conserved sequence motif that could be
present in other PRC1-interacting/stabi-
lizing lncRNAs.
The fine-tuning of BMI1 levels by FAL1
seems to have a global impact on multiple
targets of PRC1. Among the genes found
commonly regulated by FAL1 and PRC1,
Hu et al. (2014) identify CDKN1A, which
encodes for the cell cycle regulator p21.
In association with BMI1, FAL1 promotes
the repression of CDKN1A gene ex-
pression, which may account, at least in
part, for the oncogenic activity of FAL1.
Furthermore, in vivo experiments with
xenograft mice showed that downregula-
tion of FAL1 using small interfering RNA
upregulates p21 protein levels and in-
hibits tumor growth. These in vivo experi-
ments are a proof of concept for the
potential use of therapies targeting onco-
genic lncRNAs such as FAL1. The hypo-4 Elsevier Inc.thetical advantages of these
therapies would reside in
the regulatory features of
lncRNAs. In the particular
case of FAL1-targeting thera-
pies, the fine-tuning of BMI1
protein levels could translate
into a less toxic treatment
compared to the direct drug-
ging of the ubiquitously active
PRC1. Furthermore, consid-
ering the fact that lncRNA
expression tends to be stage-
and tissue-specific, their tar-
geting can potentially open
up new avenues for cancer
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